Neuphoria Therapeutics Inc
NASDAQ:NEUP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
San Fu Chemical Co Ltd
TWSE:4755
|
TW |
|
A
|
ACI Infocom Ltd
BSE:517356
|
IN |
|
3
|
3Dm Digital Manufacturing Ltd
TASE:DM3
|
IL |
|
E
|
EssilorLuxottica SA
OTC:ESLOF
|
FR |
|
Coastal Corporation Ltd
NSE:COASTCORP
|
IN |
|
Fortress Minerals Ltd
SGX:OAJ
|
MY |
|
Graphic Packaging Holding Co
NYSE:GPK
|
US |
|
Applied Graphene Materials PLC
LSE:AGM
|
UK |
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
US |
|
M
|
Meyar Co
SAU:9565
|
SA |
|
SCSK Corp
TSE:9719
|
JP |
|
S
|
Sercomm Corp
TWSE:5388
|
TW |
|
W
|
World Fuel Services Corp
XBER:WFK
|
US |
|
R
|
Remedy Entertainment Oyj
OMXH:REMEDY
|
FI |
|
Quectel Wireless Solutions Co Ltd
SSE:603236
|
CN |
|
Reconditioned Systems Inc
OTC:AMXX
|
US |
|
E
|
EFC (I) Ltd
BSE:512008
|
IN |
|
S
|
Shui-Mu International Co Ltd
TWSE:8443
|
TW |
Neuphoria Therapeutics Inc
EPS (Diluted)
Neuphoria Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Neuphoria Therapeutics Inc
NASDAQ:NEUP
|
EPS (Diluted)
-$1
|
CAGR 3-Years
-98%
|
CAGR 5-Years
-73%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Neuphoria Therapeutics Inc
Glance View
Neuphoria Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Burlington, Massachusetts and currently employs 8 full-time employees. Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company. The firm is focused on developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as needed treatment of social anxiety disorder (SAD) and for chronic treatment of post-traumatic stress disorder (PTSD). BNC210 is a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Its pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.
See Also
What is Neuphoria Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-1.2
USD
Based on the financial report for Dec 31, 2025, Neuphoria Therapeutics Inc's EPS (Diluted) amounts to -1.2 USD.
What is Neuphoria Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-73%
Over the last year, the EPS (Diluted) growth was 89%. The average annual EPS (Diluted) growth rates for Neuphoria Therapeutics Inc have been -98% over the past three years , -73% over the past five years .
